Ginsenoside Rk1 demonstrates anti-tumor effectiveness by downregulating GLS1, decreasing GSH, and subsequently accumulating ROS (Lu et al., 2022); and there are two clinical trials that use Ginsenoside in hepatocellular carcinoma(NCT01717066, NCT04523467). The gene discussed is GLS; the disease is neoplasm.